Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00676052 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

576

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: GSK233705 12.5mcg
DRUG: GSK233705 25mcg
DRUG: GSK233705 50mcg
DRUG: GSK233705 100mcg
DRUG: GSK233705 200mcg
DRUG: Placebo

Sponsor

GlaxoSmithKline